- Home
- EPSM vs GNTA Comparison
EPSM vs GNTA Comparison
Compare EPSM & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | GNTA |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | China | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 41.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EPSM | GNTA |
|---|---|---|
| Price | $2.33 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 122.7K |
| Earning Date | 12-05-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,446,963.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $1.28 |
| 52 Week High | $155.00 | $10.00 |
Technical Indicators
Market Signals| Indicator | EPSM | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 32.09 |
| Support Level | $2.20 | $1.80 |
| Resistance Level | $4.00 | $1.77 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | 0.56 | -0.02 |
| Stochastic Oscillator | 8.65 | 11.96 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.